cagrisema vs tirzepatide

cagrisema (B-tier) vs tirzepatide (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

cagrisema — tier B

semaglutide + cagrilintide. first fixed-dose GLP-1 + amylin combo. FDA review underway 2026.

semaglutide + cagrilintide. the first fixed-dose GLP-1 + amylin combo. NDA filed December 2025, expected FDA decision late 2026.

23.0% REDEFINE-1 phase 3 · half-life ~168 hours (once-weekly dosing, both components) · weight loss

tirzepatide — tier S

mounjaro and zepbound. GLP-1 plus GIP dual agonist. beats semaglutide head-to-head on weight loss.

the dual GLP-1/GIP agonist that beat semaglutide head-to-head. mounjaro for diabetes, zepbound for obesity, same molecule.

22.5% SURMOUNT-1 wt loss · half-life ~5 days · weight loss

at a glance

• cagrisema: tier B · 23.0% REDEFINE-1 phase 3
• tirzepatide: tier S · 22.5% SURMOUNT-1 wt loss

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.